Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GT307 in Advanced Colorectal Cancer
NCT06819280Recruiting
- Sponsor
- Grit Biotechnology
- Start
- Jun 2024
- Primary completion
- May 2027
- Modality
- Prophylactic Vaccines, Tumor-Infiltrating Lymphocytes (TILs), Therapeutic Vaccines
- Countries
- 1
01
Overview
Open-label, single-arm trial of GT307 in colorectal cancer (CRC), sponsored by Grit Biotechnology. Primary endpoints: Adverse Events at 3 years and Objective Response Rate at 3 years. Started Jun 2024; status: recruiting.
02
Drugs
GT307
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06819280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819280.